{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:46:00Z","timestamp":1791823560745,"version":"4.3.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Neurosci"],"DOI":"10.1038\/s41593-026-02462-2","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:54:31Z","timestamp":1791820471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigating molecular and hemodynamic effects of LSD in the human brain"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6360-5224","authenticated-orcid":false,"given":"Drummond E-Wen","family":"McCulloch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0264-2368","authenticated-orcid":false,"given":"Annette","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian H.","family":"Reveles Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Havelund","family":"Nykj\u00e6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1519","authenticated-orcid":false,"given":"Friederike","family":"Holze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Falck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Neufeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Steenstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Skov-Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Spangg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paw Patrick","family":"Randrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Steen","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Shalgunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9555-5134","authenticated-orcid":false,"given":"Sys Stybe","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-8549","authenticated-orcid":false,"given":"Marie Katrine Klose","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-6317","authenticated-orcid":false,"given":"Thomas Lund","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dea Siggaard","family":"Stenb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7811-1825","authenticated-orcid":false,"given":"Claus","family":"Svarer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-0611","authenticated-orcid":false,"given":"Patrick MacDonald","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-6866","authenticated-orcid":false,"given":"Gitte Moos","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2462_CR1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478","author":"DE Nichols","year":"2016","unstructured":"Nichols, D. E. Psychedelics. Pharmacol. Rev. https:\/\/doi.org\/10.1124\/pr.115.011478 (2016).","journal-title":"Pharmacol. Rev."},{"key":"2462_CR2","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","volume":"47","author":"F Holze","year":"2022","unstructured":"Holze, F. et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 47, 1180\u20131187 (2022).","journal-title":"Neuropsychopharmacology"},{"key":"2462_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ijnp\/pyac075","volume":"26","author":"AM Becker","year":"2023","unstructured":"Becker, A. M. et al. Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants. Int. J. Neuropsychopharmacol. 26, 97\u2013106 (2023).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"2462_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-00883-6","author":"F Holze","year":"2021","unstructured":"Holze, F. et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology https:\/\/doi.org\/10.1038\/s41386-020-00883-6 (2021).","journal-title":"Neuropsychopharmacology"},{"key":"2462_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser, P., Kirchner, K. & Passie, T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J. Psychopharmacol. 29, 57\u201368 (2015).","journal-title":"J. Psychopharmacol."},{"key":"2462_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2022.08.025","author":"F Holze","year":"2022","unstructured":"Holze, F., Gasser, P., M\u00fcller, F., Dolder, P. C. & Liechti, M. E. Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol. Psychiatry https:\/\/doi.org\/10.1016\/j.biopsych.2022.08.025 (2022).","journal-title":"Biol. Psychiatry"},{"key":"2462_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","volume":"94","author":"RJ Murphy","year":"2023","unstructured":"Murphy, R. J. et al. Acute mood-elevating properties of microdosed lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial. Biol. Psychiatry 94, 511\u2013521 (2023).","journal-title":"Biol. Psychiatry"},{"key":"2462_CR8","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.2830-16.2017","author":"V Beliveau","year":"2017","unstructured":"Beliveau, V. et al. A high-resolution in vivo atlas of the human brain\u2019s serotonin system. J. Neurosci. https:\/\/doi.org\/10.1523\/jneurosci.2830-16.2017 (2017).","journal-title":"J. Neurosci."},{"key":"2462_CR9","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon, R. A., Titeler, M. & McKenney, J. D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35, 2505\u20132511 (1984).","journal-title":"Life Sci."},{"key":"2462_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.35082","volume":"7","author":"KH Preller","year":"2018","unstructured":"Preller, K. H. et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. eLife 7, 1\u201331 (2018).","journal-title":"eLife"},{"key":"2462_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fphar.2018.00017","volume":"9","author":"T Buchborn","year":"2018","unstructured":"Buchborn, T., Lyons, T. & Kn\u00f6pfel, T. Tolerance and tachyphylaxis to head twitches induced by the 5-HT2A agonist 25CN-NBOH in mice. Front. Pharmacol. 9, 17 (2018).","journal-title":"Front. Pharmacol."},{"key":"2462_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s00213-014-3739-3","volume":"232","author":"WE Fantegrossi","year":"2015","unstructured":"Fantegrossi, W. E. et al. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT2A receptors, in mice. Psychopharmacology 232, 1039\u20131047 (2015).","journal-title":"Psychopharmacology"},{"key":"2462_CR13","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris, R. L. et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc. Natl Acad. Sci. USA 113, 4853\u20134858 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2462_CR14","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","volume":"182","author":"K Kim","year":"2020","unstructured":"Kim, K. et al. Structure of a hallucinogen-activated gq-coupled 5-HT2A serotonin receptor. Cell 182, 1574\u20131588 (2020).","journal-title":"Cell"},{"key":"2462_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57956-7","volume":"16","author":"RH Gumpper","year":"2025","unstructured":"Gumpper, R. H. et al. The structural diversity of psychedelic drug actions revealed. Nat. Commun. 16, 2734 (2025).","journal-title":"Nat. Commun."},{"key":"2462_CR16","doi-asserted-by":"publisher","first-page":"104689","DOI":"10.1016\/j.neubiorev.2022.104689","volume":"138","author":"DE-W McCulloch","year":"2022","unstructured":"McCulloch, D. E.-W. et al. Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses. Neurosci. Biobehav. Rev. 138, 104689 (2022).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"2462_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab406","author":"MK Doss","year":"2021","unstructured":"Doss, M. K. et al. Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain https:\/\/doi.org\/10.1093\/brain\/awab406 (2021).","journal-title":"Brain"},{"key":"2462_CR18","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1248\/bpb.b13-00344","volume":"36","author":"T Machida","year":"2013","unstructured":"Machida, T., Iizuka, K. & Hirafuji, M. 5-hydroxytryptamine and its receptors in systemic vascular walls. Biol. Pharm. Bull. 36, 1416\u20131419 (2013).","journal-title":"Biol. Pharm. Bull."},{"key":"2462_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/00004647-199802000-00005","volume":"18","author":"SG Hasselbalch","year":"1998","unstructured":"Hasselbalch, S. G., Madsen, P. L., Knudsen, G. M., Holm, S. & Paulson, O. B. Calculation of the FDG lumped constant by simultaneous measurements of global glucose and FDG metabolism in humans. J. Cereb. Blood Flow Metab. 18, 154\u2013160 (1998).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"2462_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1161\/01.STR.0000206440.48756.f7","volume":"37","author":"J Krejza","year":"2006","unstructured":"Krejza, J. et al. Carotid artery diameter in men and women and the relation to body and neck size. Stroke 37, 1103\u20131105 (2006).","journal-title":"Stroke"},{"key":"2462_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/mrm.25197","volume":"73","author":"DC Alsop","year":"2015","unstructured":"Alsop, D. C. et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn. Reson. Med. 73, 102\u2013116 (2015).","journal-title":"Magn. Reson. Med."},{"key":"2462_CR22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/jcbfm.2014.241","volume":"35","author":"L Zarrinkoob","year":"2015","unstructured":"Zarrinkoob, L. et al. Blood flow distribution in cerebral arteries. J. Cereb. Blood Flow Metab. 35, 648\u2013654 (2015).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"2462_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.bcp.2019.04.013","volume":"164","author":"D Luethi","year":"2019","unstructured":"Luethi, D., Hoener, M. C., Kr\u00e4henb\u00fchl, S., Liechti, M. E. & Duthaler, U. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: implications for clinical LSD use. Biochem. Pharmacol. 164, 129\u2013138 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"2462_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.neuroimage.2017.03.020","volume":"154","author":"R Ciric","year":"2017","unstructured":"Ciric, R. et al. Benchmarking of participant-level confound regression strategies for the control of motion artifact in studies of functional connectivity. Neuroimage 154, 174\u2013187 (2017).","journal-title":"Neuroimage"},{"key":"2462_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X251323364","author":"K Larsen","year":"2025","unstructured":"Larsen, K. et al. Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans. J. Cereb. Blood Flow Metab. https:\/\/doi.org\/10.1177\/0271678X251323364 (2025).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"2462_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/BF00443425","volume":"97","author":"PA Pierce","year":"1989","unstructured":"Pierce, P. A. & Peroutka, S. J. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 97, 118\u2013122 (1989).","journal-title":"Psychopharmacology"},{"key":"2462_CR27","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","volume":"99","author":"A Rickli","year":"2015","unstructured":"Rickli, A. et al. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99, 546\u2013553 (2015).","journal-title":"Neuropharmacology"},{"key":"2462_CR28","doi-asserted-by":"publisher","first-page":"pyv072","DOI":"10.1093\/ijnp\/pyv072","volume":"19","author":"PC Dolder","year":"2015","unstructured":"Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K. M. & Liechti, M. E. Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int. J. Neuropsychopharmacol. 19, pyv072 (2015).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"2462_CR29","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen, M. K. et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44, 1328\u20131334 (2019).","journal-title":"Neuropsychopharmacology"},{"key":"2462_CR30","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell, J. M. et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat. Med. 29, 2473\u20132480 (2023).","journal-title":"Nat. Med."},{"key":"2462_CR31","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025\u20131033 (2021).","journal-title":"Nat. Med."},{"key":"2462_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0893-133X(00)00126-3","volume":"23","author":"ME Liechti","year":"2000","unstructured":"Liechti, M. E., Saur, M. R., Gamma, A., Hell, D. & Vollenweider, F. X. Psychological and physiological effects of MDMA (\u201cEcstasy\u201d) after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23, 396\u2013404 (2000).","journal-title":"Neuropsychopharmacology"},{"key":"2462_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-024-03074-9","volume":"14","author":"P Vizeli","year":"2024","unstructured":"Vizeli, P. et al. Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants. Transl. Psychiatry 14, 1\u20138 (2024).","journal-title":"Transl. Psychiatry"},{"key":"2462_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.euroneuro.2024.07.003","volume":"88","author":"F Holze","year":"2024","unstructured":"Holze, F. et al. Ketanserin exhibits dose- and concentration-proportional serotonin 2A receptor occupancy in healthy individuals: relevance for psychedelic research. Eur. Neuropsychopharmacol. 88, 43\u201348 (2024).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"2462_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0893-133X(97)00044-4","volume":"17","author":"G Gr\u00fcnder","year":"1997","unstructured":"Gr\u00fcnder, G. et al. Time course of 5-HT(2A) receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 17, 175\u2013185 (1997).","journal-title":"Neuropsychopharmacology"},{"key":"2462_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1017\/S1461145707007869","volume":"11","author":"AL Nordstrom","year":"2008","unstructured":"Nordstrom, A. L. et al. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. Int. J. Neuropsychopharmacol. 11, 163\u2013171 (2008).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"2462_CR37","doi-asserted-by":"publisher","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","volume":"49","author":"S Kim","year":"2021","unstructured":"Kim, S. et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 49, D1388\u2013D1395 (2021).","journal-title":"Nucleic Acids Res."},{"key":"2462_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44016-1","volume":"14","author":"J Wallach","year":"2023","unstructured":"Wallach, J. et al. Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nat. Commun. 14, 8221 (2023).","journal-title":"Nat. Commun."},{"key":"2462_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euroneuro.2020.02.001","volume":"33","author":"MK Madsen","year":"2020","unstructured":"Madsen, M. K. et al. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. Eur. Neuropsychopharmacol. 33, 71\u201380 (2020).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"2462_CR40","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuroimage.2017.07.020","volume":"159","author":"CR Lewis","year":"2017","unstructured":"Lewis, C. R. et al. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. Neuroimage 159, 70\u201378 (2017).","journal-title":"Neuroimage"},{"key":"2462_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44153-z","volume":"13","author":"NM Rieser","year":"2023","unstructured":"Rieser, N. M. et al. Psilocybin-induced changes in cerebral blood flow are associated with acute and baseline inter-individual differences. Sci. Rep. 13, 17475 (2023).","journal-title":"Sci. Rep."},{"key":"2462_CR42","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris, R. L. et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc. Natl Acad. Sci. USA 109, 2138\u20132143 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2462_CR43","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00213-014-3446-0","volume":"231","author":"A Janowsky","year":"2014","unstructured":"Janowsky, A. et al. Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro. Psychopharmacology 231, 2771\u20132783 (2014).","journal-title":"Psychopharmacology"},{"key":"2462_CR44","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1056\/NEJM199103073241001","volume":"324","author":"P Golino","year":"1991","unstructured":"Golino, P. et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med. 324, 641\u2013648 (1991).","journal-title":"N. Engl. J. Med."},{"key":"2462_CR45","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/archneur.59.7.1084","volume":"59","author":"SJ Tepper","year":"2002","unstructured":"Tepper, S. J., Rapoport, A. M. & Sheftell, F. D. Mechanisms of action of the 5-HT1B\/1D receptor agonists. Arch. Neurol. 59, 1084\u20131088 (2002).","journal-title":"Arch. Neurol."},{"key":"2462_CR46","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.2527\/jas.2006-038","volume":"84","author":"JL Klotz","year":"2006","unstructured":"Klotz, J. L. et al. Assessment of vasoconstrictive potential of D-lysergic acid using an isolated bovine lateral saphenous vein bioassay. J. Anim. Sci. 84, 3167\u20133175 (2006).","journal-title":"J. Anim. Sci."},{"key":"2462_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1152\/physrev.1959.39.2.183","volume":"39","author":"NA Lassen","year":"1959","unstructured":"Lassen, N. A. Cerebral blood flow and oxygen consumption in man. Physiol. Rev. 39, 183\u2013238 (1959).","journal-title":"Physiol. Rev."},{"key":"2462_CR48","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","volume":"16","author":"FX Vollenweider","year":"1997","unstructured":"Vollenweider, F. X. et al. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16, 357\u2013372 (1997).","journal-title":"Neuropsychopharmacology"},{"key":"2462_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1527-3466.2004.tb00130.x","volume":"22","author":"HK Saini","year":"2004","unstructured":"Saini, H. K. et al. Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc. Drug Rev. 22, 27\u201354 (2004).","journal-title":"Cardiovasc. Drug Rev."},{"key":"2462_CR50","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cub.2016.02.010","volume":"26","author":"E Tagliazucchi","year":"2016","unstructured":"Tagliazucchi, E. et al. Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr. Biol. 26, 1043\u20131050 (2016).","journal-title":"Curr. Biol."},{"key":"2462_CR51","doi-asserted-by":"publisher","unstructured":"Avram, M. et al. Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine. Mol. Psychiatry https:\/\/doi.org\/10.1038\/s41380-024-02734-y (2024).","DOI":"10.1038\/s41380-024-02734-y"},{"key":"2462_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2023.103929","volume":"3","author":"DE-W McCulloch","year":"2023","unstructured":"McCulloch, D. E.-W. et al. Knowledge gaps in psychedelic medicalisation: preclinical and neuroimaging mechanisms. Neurosci. Appl. 3, 103929 https:\/\/doi.org\/10.1016\/j.nsa.2023.103929 (2023).","journal-title":"Neurosci. Appl."},{"key":"2462_CR53","doi-asserted-by":"publisher","unstructured":"Taylor, P. A. et al. Go figure: transparency in neuroscience images preserves context and clarifies interpretation. Nat. Methods https:\/\/doi.org\/10.1038\/s41592-026-03206-7 (2026).","DOI":"10.1038\/s41592-026-03206-7"},{"key":"2462_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.conb.2019.06.004","volume":"58","author":"PJ Drew","year":"2019","unstructured":"Drew, P. J. Vascular and neural basis of the BOLD signal. Curr. Opin. Neurobiol. 58, 61\u201369 (2019).","journal-title":"Curr. Opin. Neurobiol."},{"key":"2462_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/jcbfm.2009.188","volume":"30","author":"OB Paulson","year":"2010","unstructured":"Paulson, O. B., Hasselbalch, S. G., Rostrup, E., Knudsen, G. M. & Pelligrino, D. Cerebral blood flow response to functional activation. J. Cereb. Blood Flow Metab. 30, 2\u201314 (2010).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"2462_CR56","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuroimage.2007.10.049","volume":"40","author":"JE Perthen","year":"2008","unstructured":"Perthen, J. E., Lansing, A. E., Liau, J., Liu, T. T. & Buxton, R. B. Caffeine-induced uncoupling of cerebral blood flow and oxygen metabolism: a calibrated BOLD fMRI study. Neuroimage 40, 237\u2013247 (2008).","journal-title":"Neuroimage"},{"key":"2462_CR57","doi-asserted-by":"publisher","unstructured":"Padawer-Curry, J. A. et al. Psychedelic 5-HT2A receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function. Nat. Neurosci. https:\/\/doi.org\/10.1038\/s41593-025-02069-z (2025).","DOI":"10.1038\/s41593-025-02069-z"},{"key":"2462_CR58","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/00004647-199703000-00007","volume":"17","author":"B Biswal","year":"1997","unstructured":"Biswal, B., Hudetz, A. G., Yetkin, F. Z., Haughton, V. M. & Hyde, J. S. Hypercapnia reversibly suppresses low-frequency fluctuations in the human motor cortex during rest using echo-planar MRI. J. Cereb. Blood Flow Metab. 17, 301\u2013308 (1997).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"2462_CR59","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.neuroimage.2013.04.071","volume":"80","author":"TT Liu","year":"2013","unstructured":"Liu, T. T. Neurovascular factors in resting-state functional MRI. Neuroimage 80, 339\u2013348 (2013).","journal-title":"Neuroimage"},{"key":"2462_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/jama.2024.21972","volume":"333","author":"World Medical Association","year":"2025","unstructured":"World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants. JAMA 333, 71\u201374 (2025).","journal-title":"JAMA"},{"key":"2462_CR61","doi-asserted-by":"publisher","first-page":"125011","DOI":"10.1088\/1361-6560\/aac763","volume":"63","author":"K Gong","year":"2018","unstructured":"Gong, K. et al. Attenuation correction for brain PET imaging using deep neural network based on Dixon and ZTE MR images. Phys. Med. Biol. 63, 125011 (2018).","journal-title":"Phys. Med. Biol."},{"key":"2462_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2004.10.017","author":"C Svarer","year":"2005","unstructured":"Svarer, C. et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage https:\/\/doi.org\/10.1016\/j.neuroimage.2004.10.017 (2005).","journal-title":"Neuroimage"},{"key":"2462_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.2014.68","author":"A Ettrup","year":"2014","unstructured":"Ettrup, A. et al. Serotonin 2A receptor agonist binding in the human brain with [11 C]Cimbi-36. J. Cereb. Blood Flow Metab. https:\/\/doi.org\/10.1038\/jcbfm.2014.68 (2014).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"2462_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600493","author":"RB Innis","year":"2007","unstructured":"Innis, R. B. et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. https:\/\/doi.org\/10.1038\/sj.jcbfm.9600493 (2007).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"2462_CR65","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.neuroimage.2013.12.021","volume":"92","author":"DN Greve","year":"2014","unstructured":"Greve, D. N. et al. Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage 92, 225\u2013236 (2014).","journal-title":"Neuroimage"},{"key":"2462_CR66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1109\/TSP.2008.2005752","volume":"57","author":"MA Chappell","year":"2009","unstructured":"Chappell, M. A., Groves, A. R., Whitcher, B. & Woolrich, M. W. Variational Bayesian inference for a nonlinear forward model. IEEE Trans. Signal Process. 57, 223\u2013236 (2009).","journal-title":"IEEE Trans. Signal Process."},{"key":"2462_CR67","doi-asserted-by":"publisher","first-page":"116189","DOI":"10.1016\/j.neuroimage.2019.116189","volume":"206","author":"ET Rolls","year":"2020","unstructured":"Rolls, E. T., Huang, C.-C., Lin, C.-P., Feng, J. & Joliot, M. Automated anatomical labelling atlas 3. Neuroimage 206, 116189 (2020).","journal-title":"Neuroimage"},{"key":"2462_CR68","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/cercor\/bhab294","volume":"32","author":"MB Vestergaard","year":"2022","unstructured":"Vestergaard, M. B. et al. Human cerebral perfusion, oxygen consumption, and lactate production in response to hypoxic exposure. Cereb. Cortex 32, 1295\u20131306 (2022).","journal-title":"Cereb. Cortex"},{"key":"2462_CR69","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1177\/0271678X17737909","volume":"39","author":"MB Vestergaard","year":"2019","unstructured":"Vestergaard, M. B. & Larsson, H. B. Cerebral metabolism and vascular reactivity during breath-hold and hypoxic challenge in freedivers and healthy controls. J. Cereb. Blood Flow Metab. 39, 834\u2013848 (2019).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"2462_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-74215-5","author":"DE-W McCulloch","year":"2026","unstructured":"McCulloch, D. E.-W. et al. Multi-metric evaluations of acute psychedelic effects on fMRI brain entropy. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-026-74215-5 (2026).","journal-title":"Nat. Commun."},{"key":"2462_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-020-00711-6","author":"Y Tian","year":"2020","unstructured":"Tian, Y., Margulies, D. S., Breakspear, M. & Zalesky, A. Topographic organization of the human subcortex unveiled with functional connectivity gradients. Nat. Neurosci. https:\/\/doi.org\/10.1038\/s41593-020-00711-6 (2020).","journal-title":"Nat. Neurosci."},{"key":"2462_CR72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fninf.2014.00014","volume":"8","author":"A Abraham","year":"2014","unstructured":"Abraham, A. et al. Machine learning for neuroimaging with scikit-learn. Front. Neuroinformatics 8, 14 (2014).","journal-title":"Front. Neuroinformatics"},{"key":"2462_CR73","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00338.2011","author":"BT Yeo","year":"2011","unstructured":"Yeo, B. T. et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J. Neurophysiol. https:\/\/doi.org\/10.1152\/jn.00338.2011 (2011).","journal-title":"J. Neurophysiol."},{"key":"2462_CR74","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3389\/fpsyg.2013.00863","volume":"4","author":"D Lakens","year":"2013","unstructured":"Lakens, D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front. Psychol. 4, 863 (2013).","journal-title":"Front. Psychol."},{"key":"2462_CR75","first-page":"115","volume":"10","author":"JB Larsen","year":"2017","unstructured":"Larsen, J. B. & Rasmussen, J. B. Pharmacogenetic testing revisited: 5\u2032 nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19. Pharmacogenomics Pers. Med. 10, 115\u2013128 (2017).","journal-title":"Pharmacogenomics Pers. Med."},{"key":"2462_CR76","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.neuroimage.2015.04.025","volume":"124","author":"GM Knudsen","year":"2016","unstructured":"Knudsen, G. M. et al. The Center for Integrated Molecular Brain Imaging (CIMBI) database. Neuroimage 124, 1213\u20131219 (2016).","journal-title":"Neuroimage"}],"container-title":["Nature Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41593-026-02462-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41593-026-02462-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41593-026-02462-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:54:32Z","timestamp":1791820472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41593-026-02462-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":76,"alternative-id":["2462"],"URL":"https:\/\/doi.org\/10.1038\/s41593-026-02462-2","relation":{},"ISSN":["1097-6256","1546-1726"],"issn-type":[{"value":"1097-6256","type":"print"},{"value":"1546-1726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.E.M.\u2019s salary was previously supported by an unrestricted grant from COMPASS Pathways Ltd, which had no input on study design or manuscript preparation. G.M.K. has during the past 3 years been a consultant for Abbvie, Definium, Gilgamesh, Otsuka and Seaport Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}